In recent months, CMI began redirecting many of its efforts to better understand how the human microbiome is involved in the development and severity of COVID-19.
Researchers have since been evaluating samples from patients worldwide to find biological and epidemiological discoveries about the SARS-CoV-2 virus.
CMI director Rob Knight also noted the importance of a reliable HPC technology solution as the Center steps up its groundbreaking efforts to study the RNA microbiome, which is especially relevant because COVID-19 is an RNA virus.
CMI has been working with Panasas since 2015, when they were looking to create an HPC storage infrastructure that could deliver consistently high performance, speed data exploration and discovery, and simplify storage management for administrators.
The CMI team appreciates technology solutions that don't distract researchers from the scientific problems they aspire to solve. By freeing researchers from worries about storage, CMI can accelerate the adoption of advanced scientific technologies.
ActiveStor is a turnkey HPC storage appliance that runs the PanFS parallel file system to accelerate performance at every stage of the computational research process.
It delivers unlimited performance scaling and features a balanced node architecture that prevents hot spots and bottlenecks by automatically adapting to dynamically changing workloads and increasing demands - all at the industry's lowest total cost of ownership.
Panasas delivers high-performance computing data storage solutions that support industry and research innovation around the world.
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
INOVIO's INO-3107 Biologics License Application accepted by US FDA
ABL Bio receives upfront payment and equity investment from Eli Lilly
CARsgen Therapeutics submits two IND applications for CT0596 to Chinese regulator
Repare Therapeutics sells RP-3467 asset to Gilead Sciences for up to USD30m
Sanofi agrees USD2.2bn acquisition of Dynavax to strengthen adult vaccine portfolio
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
NeuroSense Therapeutics completes safety evaluation of PrimeC in Alzheimer's Phase 2 study
BrioHealth Solutions enrols 100th participant in BrioVAD System trial
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
Ipsen licenses Simcere Zaiming antibody-drug conjugate for global development